BioCryst inks European navenibart deal worth up to $345 million

BioCryst has signed a European licensing deal for navenibart, its investigational hereditary angioedema, or HAE, preventive therapy, with an Irish affiliate of Neopharmed Gentili. The agreement, announced May 4, 2026, gives Neopharmed Gentili exclusive commercialization rights in Europe. BioCryst said it will receive $70 million upfront, up to $275 million in regulatory and sales milestones, and tiered royalties ranging from 18% to 30%, putting the deal’s headline value at about $345 million. The companies are extending a relationship they already built through Neopharmed Gentili’s 2025 purchase of BioCryst’s European ORLADEYO business. Navenibart remains in Phase 3 development, and BioCryst says the program is on track to support a U.S. regulatory filing by the end of 2027. (ir.biocryst.com)

Why it matters: For veterinary professionals watching the broader biologics and specialty-pharma market, the deal is another sign that companies are still willing to place sizable bets on rare-disease assets with differentiated dosing profiles. BioCryst is positioning navenibart as a long-acting plasma kallikrein inhibitor, and recent company-reported interim data suggested strong attack suppression with dosing every three or six months. The transaction also strengthens BioCryst’s balance sheet, with the company saying its March 31, 2026 cash position would have risen from $260.8 million to $330.8 million on a pro forma basis after the post-quarter licensing payment. (globenewswire.com)

What to watch: The next major milestones are Phase 3 enrollment progress, additional long-term efficacy and safety readouts, and whether BioCryst stays on track for a navenibart regulatory filing by late 2027. (ir.biocryst.com)